MacroGenics stake held by Bank of America at 4.0%
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Bank of America Corporation filed an amended Schedule 13G reporting beneficial ownership of 2,556,475 shares of MacroGenics, Inc. common stock. This represents 4.0% of the class, based on 63,563,123 shares outstanding as of May 8, 2026, from MacroGenics’ May 13, 2026 Form 10-Q.
Bank of America reports no sole voting or dispositive power and shared voting and dispositive power over all 2,556,475 shares, held through wholly owned subsidiaries including BofA Securities, Inc., Bank of America N.A., Merrill Lynch International, and BofA Securities Europe SA. The filing confirms ownership of 5 percent or less of the class.
Key Figures
Key Terms
beneficial ownership financial
Schedule 13G regulatory
parent holding company regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of MacroGenics (MGNX) does Bank of America report owning in this Schedule 13G/A?
Which Bank of America subsidiaries hold the MacroGenics (MGNX) position reported on this Schedule 13G/A?
Does Bank of America report owning more than 5% of MacroGenics (MGNX)?
AI-generated analysis. How Rhea-AI works. Not financial advice.